WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Services & Solutions
Information Downloads
A New Commercial Manufacturing Facility for your Bioconjugates in Singapore
| To meet the growing bioconjugates manufacturing demands and strengthen our global dual-sourcing manufacturing network, WuXi XDC is building a state-of-the-art manufacturing facility in Singapore. Spanning a total construction area of approximately 22,000 square meters, this facility will feature cGMP manufacturing capabilities for antibody/protein intermediates, bioconjugate drug substances and drug products.
Designed to meet global regulatory standards, the Singapore site ensures that we can support clients in navigating complex regulatory landscapes and accelerating market entry. This site commenced construction in March 2024 and is on track to be operational by the end of 2025. |
Discuss This Service Overview
To discuss the information in this service overview, please complete the form on the following page to connect with our experts.
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?